INVESTOR DEADLINE ALERT: Hims & Hers Health, Inc. (HIMS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) , a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (HIMS) (NYSE: HIMS) on behalf of those who purchased or acquired HIMS securities between August 4, 2025 and July 29, 2026, inclusive.

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) HIMS shared consumers' health information with third-party advertising platforms; (2) HIMS charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them;" (3) the foregoing conduct subjected HIMS to regulatory scrutiny; (4) as a result, HIMS was reasonably likely to incur fees and penalties; and (5) as a result of the foregoing, Defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On July 29, 2026, the Federal Trade Commission ("FTC") filed a lawsuit against HIMS accusing the company of sharing customers' medical information with third-party advertisers. Specifically, the FTC's criminal complaint accuses HIMS of "deceptive and unlawful privacy practices," including sharing sensitive details about a patient's health with Snap and Facebook parent, Meta Platforms.

On this news, HIMS's stock price declined $4.32 per share, or 14.73%, to close at $25.00 per share on July 29, 2026.